Literature DB >> 14520624

Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism.

Michio Nakamura1, Shohei Fuchinoue, Satoshi Teraoka.   

Abstract

BACKGROUND: Percutaneous ethanol injection therapy (PEIT) is a noteworthy method to treat patients with renal hyperparathyroidism (RHPT). This study was performed to enable the authors to propose appropriate indications for PEIT.
METHODS: The authors injected anhydrous ethanol under ultrasonographic guidance into the parathyroid glands of 74 patients with RHPT. The size, volume, and blood vessel density of all parathyroid glands detected were evaluated.
RESULTS: The patients' mean age and hemodialysis duration were 53.8 and 14.3 years, respectively. Intact parathyroid hormone (PTH) levels decreased significantly after treatment (from 950.5 +/- 448.1 to 532.0 +/- 393.2 pg/mL [ng/L], P < 0.05), and the serum calcium and phosphorus levels as well as all bone metabolic parameters had improved. The percentage reduction was greater in cases with 1 gland over 10 mm in maximal diameter, and, as the number of glands over 10 mm rose, the percentage reduction declined. Group A was defined as patients with a small number of glands (1 or 2) with high-grade blood vessel density, and group B as patients with a larger number of such glands. The percentage reduction in intact PTH levels was significantly greater in group A than in group B (56.5 +/- 27.5% v 28.1 +/- 22.0%; P < 0.01).
CONCLUSION: the authors' analysis showed that the effectiveness of PEIT was influenced by both the number of glands detected that were more than 10 mm in maximal diameter and by the grade of blood vessel density. They identified appropriate indications for PEIT based on the predictive factors that influenced the efficacy of PEIT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14520624     DOI: 10.1016/s0272-6386(03)00910-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

Review 1.  The kidney and bone metabolism: Nephrologists' point of view.

Authors:  Masafumi Fukagawa; Yasuhiro Hamada; Shohei Nakanishi; Motoko Tanaka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 2.  Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis.

Authors:  Yoshihiro Tominaga; Susumu Matsuoka; Nobuaki Uno
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

3.  Indication and efficacy of PEIT in the management of secondary hyperparathyroidism.

Authors:  Fumihiko Koiwa; Takeshi Hasegawa; Reika Tanaka; Takatoshi Kakuta
Journal:  NDT Plus       Date:  2008-08

4.  Percutaneous ethanol injection therapy for advanced renal hyperparathyroidism in Japan: 2004 survey by the Japanese Society for Parathyroid Intervention.

Authors:  Takatoshi Kakuta; Masafumi Fukagawa; Masafumi Kitaoka; Fumihiko Koiwa; Noritaka Onoda; Yasuhiro Tominaga; Tadao Akizawa; Kiyoshi Kurokawa
Journal:  NDT Plus       Date:  2008-08

5.  Long-term prognosis of parathyroid function in chronic dialysis patients after PEIT-a single-centre trial.

Authors:  Reika Tanaka; Takatoshi Kakuta; Fumihiko Koiwa; Masafumi Fukagawa; Akira Saito
Journal:  NDT Plus       Date:  2008-08

6.  New clinical guidelines for selective direct injection therapy of the parathyroid glands in chronic dialysis patients.

Authors:  Noritaka Onoda; Masafumi Fukagawa; Yoshihiro Tominaga; Masafumi Kitaoka; Tadao Akizawa; Fumihiko Koiwa; Takatoshi Kakuta; Kiyoshi Kurokawa
Journal:  NDT Plus       Date:  2008-08

7.  Effects of percutaneous ethanol injection therapy on subsequent surgical parathyroidectomy.

Authors:  Michio Nakamura; Yuji Marui; Yoshifumi Ubara; Shohei Nakanishi; Fumi Takemoto; Kenmei Takaichi; Shinji Tomikawa
Journal:  NDT Plus       Date:  2008-08

8.  Medical management after parathyroid intervention.

Authors:  Motoko Tanaka; Masafumi Fukagawa
Journal:  NDT Plus       Date:  2008-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.